Google
XAIR — BEYOND AIR INC (Healthcare >> Medical Devices)
XAIR FAQ
What is XAIR's ROE?
BEYOND AIR INC reports a Return on Equity (ROE) of -382.21%.
What is XAIR's dividend yield?
BEYOND AIR INC offers a dividend yield of 0.00%.
What is XAIR's Deepscope Quality Score?
Deepscope rates XAIR's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy XAIR?
Deepscope's AI Timing Score for XAIR is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does XAIR belong to?
BEYOND AIR INC is classified under the Healthcare >> Medical Devices sector on the NASDAQ exchange.
|
USD 0.44
Price
-0.03
(-6.00%)
Day Change
|
|
|---|
XAIR, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 82 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.44 |
| PBV / Sector |
0.72 / 7.31
GREAT
|
| Earning Per Share | -2.30 |
| PE / Sector |
N/A / 28.52
|
| PEG or PE/Growth / Sector |
N/A / 0.39
|
| Average 1M Daily Value |
0.12 M
GREAT
|
| Average 1W Daily Value |
0.10 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
43% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-04 09:24:03 |
| Symbol | XAIR |
| Name | BEYOND AIR INC |
| Sector | Healthcare >> Medical Devices |
| Market | NASDAQ |
| Listed Shares | 12.69 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 5.97 / 17,902.07 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 900 Stewart Avenue, Garden City, NY, United States, 11530
Phone: 516 665 8200
Website: https://www.beyondair.net
Employees: 61
Sector: Healthcare >> Medical Devices
Description: Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home. In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
ME vs SECTOR Healthcare >> Medical Devices
Click a bubble to view stock details · Bubble size represents market capitalization share
